A New Heart Damage Marker Combined With BNP Improves Risk Assessment in Dialysis Patients
The ratio of heart-type fatty acid-binding protein (hFABP) to myoglobin, combined with BNP, improved detection of cardiac damage and volume overload in dialysis patients beyond either marker alone.
Quick Facts
What This Study Found
The hFABP/myoglobin ratio combined with BNP improved detection of cardiac damage and volume overload in dialysis patients, providing a multi-marker approach that overcomes renal clearance confounding of individual markers.
Key Numbers
How They Did This
Cross-sectional study in dialysis patients. hFABP, myoglobin, BNP, ANP, and cardiac function parameters measured. The hFABP/myoglobin ratio developed to normalize for renal clearance effects.
Why This Research Matters
Single biomarkers have limitations in kidney failure patients. Multi-marker approaches that account for renal confounding improve diagnostic accuracy for this extremely high-risk population.
The Bigger Picture
Precision diagnostics in complex patients requires multi-marker panels that account for confounding factors. This approach models how cardiac biomarker science evolves for challenging populations.
What This Study Doesn't Tell Us
Cross-sectional design. The specific hFABP/myoglobin ratio cutoffs need validation. Dialysis timing affects all markers.
Questions This Raises
- ?Should multi-marker panels be standard in dialysis patient cardiac assessment?
- ?Does the ratio predict cardiac events in dialysis patients?
- ?Can this approach reduce unnecessary cardiac testing in dialysis?
Trust & Context
- Key Stat:
- Multi-marker improvement No single marker was perfect in dialysis patients — combining hFABP/myoglobin ratio + BNP captured both damage AND overload better than any alone
- Evidence Grade:
- Moderate evidence from a comparative biomarker study in a clinically challenging population with novel ratio development.
- Study Age:
- Published in 2003. Multi-marker cardiac assessment in renal failure patients has evolved with additional novel biomarkers.
- Original Title:
- Serum ratio of heart-type fatty acid-binding protein to myoglobin. A novel marker of cardiac damage and volume overload in hemodialysis patients.
- Published In:
- Nephron. Clinical practice, 93(2), C69-74 (2003)
- Authors:
- Furuhashi, Masato(2), Ura, Nobuyuki, Hasegawa, Koichi, Yoshida, Hideaki, Tsuchihashi, Kazufumi, Nakata, Tomoaki, Shimamoto, Kaxuaki
- Database ID:
- RPEP-00818
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Why are heart tests harder in dialysis patients?
Kidney failure changes how the body clears heart markers from the blood, making single measurements unreliable. Using ratios of markers (hFABP/myoglobin) and combining with BNP overcomes this problem.
Should dialysis patients get multiple heart markers?
This study supports yes — no single marker captures both heart damage and fluid overload in dialysis. Combining markers provides a more complete and accurate cardiac risk picture.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00818APA
Furuhashi, Masato; Ura, Nobuyuki; Hasegawa, Koichi; Yoshida, Hideaki; Tsuchihashi, Kazufumi; Nakata, Tomoaki; Shimamoto, Kaxuaki. (2003). Serum ratio of heart-type fatty acid-binding protein to myoglobin. A novel marker of cardiac damage and volume overload in hemodialysis patients.. Nephron. Clinical practice, 93(2), C69-74.
MLA
Furuhashi, Masato, et al. "Serum ratio of heart-type fatty acid-binding protein to myoglobin. A novel marker of cardiac damage and volume overload in hemodialysis patients.." Nephron. Clinical practice, 2003.
RethinkPeptides
RethinkPeptides Research Database. "Serum ratio of heart-type fatty acid-binding protein to myog..." RPEP-00818. Retrieved from https://rethinkpeptides.com/research/furuhashi-2003-serum-ratio-of-hearttype
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.